At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 19, 2026 at 16:12 ET
Solid Biosciences reported financial results for Q4 and full year 2025, highlighted by strong pipeline progress across its gene therapy programs, including positive interim Phase 1/2 data for SGT-003 in Duchenne, first patient dosed in the FALCON trial for SGT-212 in Friedreich’s ataxia, and upcoming trials for SGT-501 in CPVT. The company also completed a $240 million private placement, extending its cash runway into H1 2028.
- Positive interim Phase 1/2 INSPIRE DUCHENNE data showed robust microdystrophin expression, restoration of DAPC components, and stabilization of cardiac function.
- First participant dosed in Phase 1b FALCON trial for SGT-212 in Friedreich’s ataxia; well tolerated with no treatment-related adverse events.
- Clinical sites activated for Phase 1b ARTEMIS trial of SGT-501 in CPVT; first dosing expected in Q2 2026.
- Company aligned with FDA on Phase 3 IMPACT DUCHENNE trial design; first dosing expected in April 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access